| Literature DB >> 22022607 |
Yi-Ching Ong1, Jon P Boyle, John C Boothroyd.
Abstract
Toxoplasma gondii has a remarkable ability to infect an enormous variety of mammalian and avian species. Given this, it is surprising that three strains (Types I/II/III) account for the majority of isolates from Europe/North America. The selective pressures that have driven the emergence of these particular strains, however, remain enigmatic. We hypothesized that strain selection might be partially driven by adaptation of strains for mammalian versus avian hosts. To test this, we examine in vitro, strain-dependent host responses in fibroblasts of a representative avian host, the chicken (Gallus gallus). Using gene expression profiling of infected chicken embryonic fibroblasts and pathway analysis to assess host response, we show here that chicken cells respond with distinct transcriptional profiles upon infection with Type II versus III strains that are reminiscent of profiles observed in mammalian cells. To identify the parasite drivers of these differences, chicken fibroblasts were infected with individual F1 progeny of a Type II x III cross and host gene expression was assessed for each by microarray. QTL mapping of transcriptional differences suggested, and deletion strains confirmed, that, as in mammalian cells, the polymorphic rhoptry kinase ROP16 is the major driver of strain-specific responses. We originally hypothesized that comparing avian versus mammalian host response might reveal an inversion in parasite strain-dependent phenotypes; specifically, for polymorphic effectors like ROP16, we hypothesized that the allele with most activity in mammalian cells might be less active in avian cells. Instead, we found that activity of ROP16 alleles appears to be conserved across host species; moreover, additional parasite loci that were previously mapped for strain-specific effects on mammalian response showed similar strain-specific effects in chicken cells. These results indicate that if different hosts select for different parasite genotypes, the selection operates downstream of the signaling occurring during the beginning of the host's immune response.Entities:
Mesh:
Year: 2011 PMID: 22022607 PMCID: PMC3192797 DOI: 10.1371/journal.pone.0026369
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Type II and Type III strains induce distinct transcriptional programs in chicken embryonic fibroblasts.
Microarray analysis of SL-29 chicken embryonic fibroblasts subjected to mock, Type II (ME49), or Type III (CEP) infection. 2 biological replicates were performed for each treatment and RNA was harvested at 24 hours post-infection. Genes shown are those identified as significantly up-regulated by SAM analysis (FDR<5% and fold change ≥1.5) either in Type III infection over Type II infection (A) or in Type II infection over Type III infection (B). For heatmap representation, probe intensities were log2-transformed and median centered by row; unsupervised hierarchical clustering was then performed (cluster numbers indicated on left). The color gradient key at top represents the color range in a log2 scale, from relative upregulation by 2-fold (yellow) and relative downregulation by 2-fold (blue).
Gene sets from the Molecular Signatures Database CGP (chemical and genetic perturbations) library identified by GSEA as significantly enriched in Type III-induced genes.
| NAME | FDR q-val |
| NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON | 0.04 |
| SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN | 0.05 |
| RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_DN | 0.05 |
| SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_DN | 0.06 |
| BEIER_GLIOMA_STEM_CELL_UP | 0.09 |
| GAUSSMANN_MLL_AF4_FUSION_TARGETS_D_UP | 0.10 |
| SATO_SILENCED_EPIGENETICALLY_IN_PANCREATIC_CANCER | 0.10 |
| RICKMAN_HEAD_AND_NECK_CANCER_F | 0.10 |
| WANG_BARRETTS_ESOPHAGUS_UP | 0.11 |
| KLEIN_PRIMARY_EFFUSION_LYMPHOMA_UP | 0.15 |
| GU_PDEF_TARGETS_DN | 0.15 |
| NAKAYAMA_SOFT_TISSUE_TUMORS_PCA2_DN | 0.15 |
| ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP | 0.16 |
| SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP | 0.17 |
| LI_CISPLATIN_RESISTANCE_DN | 0.21 |
| RICKMAN_HEAD_AND_NECK_CANCER_E | 0.22 |
| HELLER_SILENCED_BY_METHYLATION_DN | 0.22 |
| HANN_RESISTANCE_TO_BCL2_INHIBITOR_DN | 0.23 |
| BROWNE_HCMV_INFECTION_18HR_DN | 0.23 |
| VALK_AML_WITH_FLT3_ITD | 0.23 |
Gene sets with a false-discovery rate (FDR) q-val≤0.25 were considered significant and are listed here.
Gene sets from the Molecular Signatures Database CGP (chemical and genetic perturbations) library identified by GSEA as significantly enriched in Type II-induced genes.
| NAME | FDR q-val |
| SANA_TNF_SIGNALING_UP | 0 |
| HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN | 0.04 |
| JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN | 0.04 |
| HINATA_NFKB_TARGETS_KERATINOCYTE_UP | 0.04 |
| FARMER_BREAST_CANCER_CLUSTER_1 | 0.05 |
| LINDSTEDT_DENDRITIC_CELL_MATURATION_A | 0.05 |
| HINATA_NFKB_TARGETS_FIBROBLAST_UP | 0.07 |
| DAZARD_RESPONSE_TO_UV_SCC_UP | 0.07 |
| TRAYNOR_RETT_SYNDROM_UP | 0.08 |
| REN_ALVEOLAR_RHABDOMYOSARCOMA_UP | 0.08 |
| BROWNE_INTERFERON_RESPONSIVE_GENES | 0.08 |
| CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS | 0.09 |
| DER_IFN_GAMMA_RESPONSE_UP | 0.09 |
| DUTTA_APOPTOSIS_VIA_NFKB | 0.13 |
| XU_HGF_SIGNALING_NOT_VIA_AKT1_48HR_UP | 0.13 |
| ZUCCHI_METASTASIS_DN | 0.13 |
| TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN | 0.14 |
| XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN | 0.14 |
| GEISS_RESPONSE_TO_DSRNA_UP | 0.15 |
| ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP | 0.15 |
| COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN | 0.15 |
| LIANG_SILENCED_BY_METHYLATION_2 | 0.16 |
| LINDSTEDT_DENDRITIC_CELL_MATURATION_B | 0.25 |
Gene sets with a false-discovery rate (FDR) q-val≤0.25 were considered significant and are listed here.
Functional categories identified by DAVID as significantly enriched (FDR<25%) in Type III-induced genes.
| Term | FDR (%) |
| GO:0005576∼extracellular region | 0.0000033 |
| gga04512:ECM-receptor interaction | 0.0022 |
| signal | 0.0077 |
| GO:0044421∼extracellular region part | 0.0089 |
| signal peptide | 0.042 |
| gga04510:Focal adhesion | 0.062 |
| GO:0031012∼extracellular matrix | 0.18 |
| glycoprotein | 0.18 |
| GO:0040008∼regulation of growth | 0.43 |
| Secreted | 0.38 |
| GO:0009968∼negative regulation of signal transduction | 0.52 |
| GO:0005578∼proteinaceous extracellular matrix | 0.50 |
| GO:0010648∼negative regulation of cell communication | 0.70 |
| GO:0045177∼apical part of cell | 0.56 |
| GO:0007167∼enzyme linked receptor protein signaling pathway | 0.96 |
| GO:0007155∼cell adhesion | 1.08 |
| GO:0022610∼biological adhesion | 1.08 |
| disulfide bond | 0.96 |
| IPR000980:SH2 motif | 1.25 |
| GO:0005887∼integral to plasma membrane | 1.11 |
| glycosylation site:N-linked (GlcNAc…) | 1.41 |
| GO:0031226∼intrinsic to plasma membrane | 1.28 |
| IPR001496:SOCS protein, C-terminal | 1.94 |
| SM00252:SH2 | 2.15 |
| GO:0051240∼positive regulation of multicellular organismal process | 3.28 |
| SM00253:SOCS | 2.58 |
| GO:0006928∼cell motion | 4.63 |
| disulfide bond | 6.54 |
| GO:0007169∼transmembrane receptor protein tyrosine kinase signaling pathway | 8.40 |
| GO:0001568∼blood vessel development | 8.84 |
| GO:0007242∼intracellular signaling cascade | 10.62 |
| GO:0001944∼vasculature development | 10.75 |
| Signal transduction inhibitor | 8.49 |
| IPR013320:Concanavalin A-like lectin/glucanase, subgroup | 9.92 |
| GO:0031175∼neuron projection development | 11.93 |
| GO:0051094∼positive regulation of developmental process | 12.34 |
| GO:0030030∼cell projection organization | 13.48 |
| Immunoglobulin domain | 10.33 |
| GO:0040014∼regulation of multicellular organism growth | 15.59 |
| GO:0001525∼angiogenesis | 16.06 |
| gga04630:Jak-STAT signaling pathway | 10.60 |
| GO:0048514∼blood vessel morphogenesis | 16.36 |
| short sequence motif:Cell attachment site | 13.94 |
| IPR013098:Immunoglobulin I-set | 14.57 |
| GO:0005886∼plasma membrane | 13.72 |
| IPR012680:Laminin G, subdomain 2 | 15.80 |
| GO:0019838∼growth factor binding | 16.18 |
| IPR001791:Laminin G | 19.14 |
Functional categories identified by DAVID as significantly enriched (FDR<25%) in Type II-induced genes.
| Term | FDR (%) |
| GO:0044421∼extracellular region part | 0.0016 |
| GO:0005576∼extracellular region | 0.0027 |
| GO:0051249∼regulation of lymphocyte activation | 0.016 |
| GO:0002694∼regulation of leukocyte activation | 0.025 |
| GO:0050865∼regulation of cell activation | 0.044 |
| GO:0042981∼regulation of apoptosis | 0.093 |
| GO:0043067∼regulation of programmed cell death | 0.11 |
| GO:0010941∼regulation of cell death | 0.12 |
| GO:0050863∼regulation of T cell activation | 0.12 |
| GO:0005125∼cytokine activity | 0.12 |
| GO:0006955∼immune response | 0.19 |
| GO:0043068∼positive regulation of programmed cell death | 0.19 |
| GO:0043065∼positive regulation of apoptosis | 0.19 |
| GO:0010942∼positive regulation of cell death | 0.21 |
| GO:0002250∼adaptive immune response | 0.21 |
| GO:0002460∼adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 0.21 |
| GO:0045619∼regulation of lymphocyte differentiation | 0.65 |
| GO:0051251∼positive regulation of lymphocyte activation | 0.73 |
| GO:0005615∼extracellular space | 0.58 |
| GO:0002696∼positive regulation of leukocyte activation | 0.93 |
| GO:0002684∼positive regulation of immune system process | 0.97 |
| GO:0042127∼regulation of cell proliferation | 0.97 |
| GO:0050867∼positive regulation of cell activation | 1.17 |
| GO:0019724∼B cell mediated immunity | 1.58 |
| GO:0002449∼lymphocyte mediated immunity | 2.03 |
| GO:0031012∼extracellular matrix | 2.69 |
| GO:0002443∼leukocyte mediated immunity | 3.79 |
| cytokine | 3.24 |
| GO:0043383∼negative T cell selection | 4.50 |
| GO:0045060∼negative thymic T cell selection | 4.50 |
| signal peptide | 3.69 |
| GO:0008285∼negative regulation of cell proliferation | 4.76 |
| GO:0050870∼positive regulation of T cell activation | 5.14 |
| GO:0000122∼negative regulation of transcription from RNA polymerase II promoter | 5.33 |
| GO:0045580∼regulation of T cell differentiation | 5.34 |
| gga04514:Cell adhesion molecules (CAMs) | 3.74 |
| GO:0046649∼lymphocyte activation | 7.99 |
| GO:0048048∼embryonic eye morphogenesis | 9.03 |
| GO:0005578∼proteinaceous extracellular matrix | 6.78 |
| GO:0030098∼lymphocyte differentiation | 9.60 |
| GO:0042110∼T cell activation | 11.20 |
| GO:0045061∼thymic T cell selection | 11.73 |
| GO:0051250∼negative regulation of lymphocyte activation | 11.73 |
| GO:0002695∼negative regulation of leukocyte activation | 11.73 |
| signal | 9.10 |
| GO:0045321∼leukocyte activation | 13.40 |
| GO:0009986∼cell surface | 10.01 |
| GO:0002252∼immune effector process | 14.67 |
| Secreted | 11.18 |
| GO:0050866∼negative regulation of cell activation | 17.84 |
| GO:0045089∼positive regulation of innate immune response | 17.84 |
| GO:0007155∼cell adhesion | 20.73 |
| GO:0022610∼biological adhesion | 20.73 |
| GO:0045088∼regulation of innate immune response | 21.17 |
| GO:0016064∼immunoglobulin mediated immune response | 21.17 |
| GO:0002521∼leukocyte differentiation | 21.27 |
| GO:0001775∼cell activation | 22.37 |
| GO:0030217∼T cell differentiation | 22.77 |
| GO:0005604∼basement membrane | 17.39 |
| GO:0009897∼external side of plasma membrane | 17.72 |
| GO:0016564∼transcription repressor activity | 20.13 |
| GO:0045892∼negative regulation of transcription, DNA-dependent | 24.25 |
| GO:0050778∼positive regulation of immune response | 24.56 |
| GO:0045058∼T cell selection | 24.62 |
| GO:0045596∼negative regulation of cell differentiation | 26.21 |
| gga00982:Drug metabolism | 17.83 |
| gga00980:Metabolism of xenobiotics by cytochrome P450 | 17.83 |
Figure 2Genome-wide QTL map of strain-specific differences in host gene expression in infected chicken embryonic fibroblasts.
SL-29 chicken embryonic fibroblasts were infected with 21 F1 progeny from a Type II x Type III cross and host gene expression at 24 hours post-infection was profiled by microarray. A one-dimensional genome-wide scan was conducted to identify Toxoplasma genetic markers associated with the expression level of each of the host genes represented on the microarray. The output of this QTL analysis is graphed here, where each line represents a host gene that mapped with a LOD score >2 to a Toxoplasma locus. To determine significance, p-values were calculated based on 500 permutations; genes that mapped to a parasite genetic locus with a p-value of <0.05 were considered significant. Threshold LOD scores for this p-value varied on a gene-by-gene basis from 2.10 to 3.14 and are represented by the two dotted gray lines overlaying the graph.
Genome-wide QTL mapping of strain-specific host transcriptional response in chicken embryonic fibroblasts.
| Number of genes mapping | ||
| Chromosome | p<0.05 | p<0.05 Type II vs. III fold-change ≥1.5 |
| Ia | 115 | 2 |
| Ib | 1 | 0 |
| II | 10 | 0 |
| III | 14 | 4 |
| IV | 1 | 0 |
| V | 0 | 0 |
| VI | 0 | 0 |
| VIIa | 304 | 39 |
| VIIb | 137 | 98 |
| VIII | 22 | 1 |
| IX | 0 | 0 |
| X | 70 | 16 |
| XI | 9 | 0 |
| XII | 6 | 0 |
Expression values of each gene were treated as phenotypes and a one-dimensional genome scan to detect major QTL associated with these expression values was performed. For each gene, the parasite genomic locus corresponding to the maximum LOD score was determined. p-values were calculated by permutation test and only genes with maximum LOD scores meeting the p<0.05 cutoff were considered significant.
Functional categories identified by DAVID as significantly enriched (FDR<25%) in the set of genes mapping to chromosome VIIb.
| Term | Fold Enrichment | FDR (%) |
| IPR000980:SH2 motif | 17.10 | 0.021 |
| SM00252:SH2 | 14.28 | 0.031 |
| IPR001496:SOCS protein, C-terminal | 37.05 | 0.14 |
| SM00253:SOCS | 30.95 | 0.17 |
| Signal transduction inhibitor | 40.01 | 2.21 |
| GO:0009968∼negative regulation of signal transduction | 10.18 | 8.62 |
| GO:0005576∼extracellular region | 2.54 | 9.44 |
| GO:0010648∼negative regulation of cell communication | 9.63 | 9.98 |
| GO:0031175∼neuron projection development | 7.70 | 17.65 |
| GO:0030182∼neuron differentiation | 5.15 | 18.26 |
| GO:0005578∼proteinaceous extracellular matrix | 4.63 | 18.37 |
| GO:0031012∼extracellular matrix | 4.38 | 21.63 |
| domain:SOCS box | 84.84 | 22.75 |
| gga04910:Insulin signaling pathway | 5.41 | 22.90 |
| Secreted | 2.94 | 23.19 |
| gga04630:Jak-STAT signaling pathway | 5.26 | 24.42 |
Comparison of genes significantly up-regulated by Type I versus Type I Δrop16 infection or Type III versus Type II infection.
| GENE SYMBOL | Fold Change, I>I Δrop16, 5 hpi | Fold Change, III>II, 24 hpi |
| CCL17 | 21.2 | 399.6 |
| CA2 | 8.2 | 25.7 |
| --- | 7.4 | |
| --- | 4.1 | 16.2 |
| CALCA | 4.1 | |
| LOC424241 | 4.1 | |
| CXCR4 | 3.6 | |
| SOCS1 | 3.4 | 14.7 |
| CISH | 3.2 | 5.8 |
| BMP2 | 3.1 | |
| DOK5 | 2.9 | 3.2 |
| PPP1R3C | 2.6 | 6.6 |
| SERPINB2 | 2.6 | 6.2 |
| EAF2 | 2.4 | 3.6 |
| SOCS2 | 2.3 | 6.5 |
| UGP2 | 2.2 | 3.6 |
| RDH10 | 2.1 | 2.8 |
| KRT14 | 2.1 | 2.9 |
| NPTX2 | 2.0 | |
| --- | 2.0 | 5.2 |
| --- | 1.9 | |
| --- | 1.9 | |
| SOCS3 | 1.9 | 3.8 |
| FST | 1.9 | 4.6 |
| CCL4 | 1.8 | |
| LOC395581 | 1.7 | |
| LOC422150 | 1.7 | |
| TNFRSF1B | 1.6 | |
| WDFY2 | 1.6 | 4.6 |
| PLK2 | 1.6 | |
| APPL2 | 1.6 | 3.2 |
| SGK1 | 1.6 | |
| --- | 1.6 | |
| --- | 1.5 | 2.8 |
| MEOX2 | 1.5 | 3.2 |
| --- | 1.5 | |
| SEMA3A | 1.5 | 4.6 |
All genes identified as significantly up-regulated (≥1.5 fold-change, p<0.05) between chicken embryonic fibroblasts infected with Type I versus Type I Δrop16 parasites are shown here. Bold-face font indicates genes identified as mapping to chromosome VIIb. Where more than one probe corresponded to a given gene, the highest fold-change difference is shown.